Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers

NCT00332956 is registered in ClinicalTrials.gov with DynPort Vaccine Company LLC, A GDIT Company as lead sponsor.

NCT NCT00332956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00332956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
October 31, 2008
Enrollment
400 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers